Navigation Links
Despite Decline in Share of Global Output, U.S. Science Impact Still Strong, Says Thomson Reuters
Date:1/28/2009

PHILADELPHIA and LONDON, Jan. 28 /PRNewswire/ -- The Scientific business of Thomson Reuters today announced the results of a study showing that the United States' share of scientific research output continues to shrink while Asia-Pacific's share of output rises. Nevertheless, the U.S. retains a healthy footing globally in the relative impact of its research.

In its January/February issue of Science Watch, Thomson Reuters analyzes 12 year's worth of data from its National Science Indicators database to determine the U.S.'s global scientific influence based on the nation's research output and impact.

In 2005, Science Watch noted that the U.S.'s output, as a percentage of world science, was in decline, with Asia-Pacific's output steadily rising. This latest analysis shows the trends continuing. In 2005, the U.S. contributed 32.8 percent of global research; by 2007 its share slid to 31.5 percent. During the same period, Asia-Pacific's share increased from 25.9 percent to 28.2 percent.

"It is important to note that measuring scientific output is only one way to measure a country's influence in the sciences," said Christopher King, editor of Science Watch. "Because citations are an acknowledgement of intellectual debt, we also evaluate a country's citation impact. The U.S.'s citation impact has remained strong in the major science fields."

In all 21 science fields analyzed for this report, the U.S. markedly surpassed the world average in citation impact. Topping the list was Physics, where the U.S. exceeded the world mark by 55 percent, followed by Chemistry and Materials Science where the U.S. exceeded the world by 52 percent and 47 percent, respectively.

For more information about U.S. research output and impact, including expert analysis, visit ScienceWatch.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Fadel Partners Announces 13% Growth Despite IT Services Industry Downtrend
2. Despite Economic Woes, Physician Compensation Increases
3. Investment and Growth in US Medical Technology Industry Continues Despite Challenging Public Markets
4. Multigene Test Predicts Who Could Avoid Chemotherapy Despite Positive Lymph Nodes in Early Breast Cancer
5. Cell Therapeutics Net Loss Declines as Operating Expenses Decrease By 58% in Third Quarter 2008
6. Data show a decline in cystic fibrosis since introduction of prenatal carrier screening
7. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
8. Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders
9. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
10. IntraLinks Poll: Half of Clinical Trial Management Professionals Share Critical Information Via E-Mail
11. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... company focused on the development of autologous cell ... the International Society for Cellular Therapy (ISCT) on ... currently in a Phase 1/2 clinical trial.  The ... from 5:30 PM to 7:00 PM local time, ...
(Date:5/20/2015)... SAN FRANCISCO, Calif. , May 20, 2015 ... VCYT ) today presented preliminary data demonstrating the ... distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial ... The findings suggest the classifier,s potential to help ... surgery to resolve ambiguity in IPF diagnosis – ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) ... Therapy Market Outlook 2020 " report to their ... and regenerative medicine is expected to have huge marketing ... help in the growth of deregulated organs. Several therapeutic ... unable to form new tissue or sometimes organ transplant ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... Diagnostics Inc.,(TSX: SDI) today announced that its Endotoxin ... of sepsis, will be used to measure,endotoxin levels ... III sub study,part of a multinational clinical trial ... severe sepsis., "Spectral is pleased that a ...
... Cytopia Limited,(ASX: CYT) today announced that it is ... Association for Cancer Research Annual Meeting being held,in ... from around the world to discuss new and ... "A Novel JAK2 inhibitor for the treatment of,myeloproliferative ...
... Blacksburg, Va. -- Fullerenes, also fondly known as buckyballs, ... 1985, the hollow carbon atoms have been adapted for ... of imaging materials. , It appears that the ... water, forming aggregates of thousands of molecules. And there ...
Cached Biology Technology:Spectral's EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy 2Citrate appears to control buckyball clumping but environmental concerns remain 2Citrate appears to control buckyball clumping but environmental concerns remain 3
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... for the 2015 New York Design Awards under the ... New York City Design Awards are part of a ... over 2,500 ratings from the marketplace, industry and judging ...
(Date:4/13/2015)... a leading cloud-based consumer engagement platform that provides trusted ... communities around health and wellness, announced today the launching ... The ... vehicle to receive validated health information from consumers. ... will allow higi,s trusted partners, on a user opt-in ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... 14, 2013 -- The following statement was issued today by ... Society (WCS) today celebrates the decision by an historic, broad ... new sharks, freshwater sawfish, and two manta ray species for ... of Wild Fauna and Flora (CITES). This vote is a ...
... used synonymously with "boring," as in that story or ... biology seeking to engineer valuable new microbes, however, predictability ... with the multi-institutional partnership known as BIOFAB have become ... this ring by unveiling a package of public domain ...
... MWG Operon and School of Biological and Chemical Sciences, Queen ... on the genome sequencing analysis of Ash ( Fraxinus excelsior ... our understanding of the wide spreading fungal tree disease ... northern Europe and has already been found at more than ...
Cached Biology News:Predictability: The brass ring for synthetic biology 2Eurofins MWG Operon and Queen Mary, University Of London commence genome sequencing analysis of Ash 2
Request Info...
Recombinant Mouse sTNF RII/TNFRSF1B...
One-step, microplate or cuvet, colorimetric, linear detection range 0.2 mg/dL to 20 mg/dL. Procedure: 20 min....
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
Biology Products: